The basis for the disparate sensitivity of L1210 leukemia and Walker 256 carcinoma to a new triazine folate antagonist.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001692:Biological Transport; D002279:Carcinoma 256, Walker / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003857:Deoxyuridine / Q000378:metabolism; D005493:Folic Acid Antagonists / Q000378:metabolism / Q000627:therapeutic use*; D066298:In Vitro Techniques; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D008727:Methotrexate / Q000494:pharmacology; D051379:Mice; D051381:Rats; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism; D014227:Triazines / Q000378:metabolism / Q000627:therapeutic use*; D014316:Tritium
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D005493:Folic Acid Antagonists; D014227:Triazines; D014316:Tritium; D013762:Tetrahydrofolate Dehydrogenase; D003857:Deoxyuridine; D008727:Methotrexate